SCHEMBL277495

SCHEMBL277495

NC(=O)COc1ccc(Cl)cc1Cl

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.72
TSHR P16473 3/20 0.64
SMN1; SMN2 Q16637 5/20 0.63
HTT P42858 1/20 0.59
MAPT P10636 4/20 0.57
HPGD P15428 2/20 0.57
GAA P10253 1/20 0.57
ALOX12 P18054 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
RECQL P46063 1/20 0.57
NPC1 O15118 3/20 0.56
RAB9A P51151 3/20 0.56
ALDH1A1 P00352 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
LMNA P02545 3/20 0.56
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
TP53 P04637 1/20 0.55
PKM P14618 1/20 0.55
MAPK1 P28482 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyrimidine SCHEMBL27645369 0.88 HPGD (0.58) TDP1TSHRSMN1; SMN2HTTMAPT
2,4-Dichlorophenoxyacetic Acid SCHEMBL8160161 0.85 TDP1 (0.87) TDP1TSHRSMN1; SMN2HTTMAPT
2,4-Dichlorophenoxyacetic Acid SCHEMBL1765635 0.84 TDP1 (0.93) TDP1TSHRSMN1; SMN2HTTMAPT
SCHEMBL15651938 0.84 TDP1 (0.51) TDP1TSHRSMN1; SMN2HTTHPGD
2,4-Dichlorophenoxyacetic Acid SCHEMBL27783 0.84 TDP1 (1.00) TDP1TSHRSMN1; SMN2HTTMAPT
2,4-Dichlorophenoxyacetic Acid SCHEMBL226803 0.84 TDP1 (1.00) TDP1TSHRSMN1; SMN2HTTMAPT
SCHEMBL11639157 0.84 TDP1 (0.74) TDP1TSHRSMN1; SMN2HTTMAPT
2,4-Dichlorophenoxyacetic Acid SCHEMBL11716042 0.84 TDP1 (1.00) TDP1TSHRSMN1; SMN2HTTMAPT
2,4-Dichlorophenoxyacetic Acid SCHEMBL31108925 0.84 TDP1 (1.00) TDP1TSHRSMN1; SMN2HTTMAPT
SCHEMBL2538911 0.84 TDP1 (0.74) TDP1TSHRSMN1; SMN2HTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-121584674-A Intelligent energy storage regulation and control method and system for dynamic voltage regulation of power grid 国网冀北电力有限公司唐山供电公司 2026-02-27 CN claimed
EP-3967981-B1 METHOD FOR PURCHASE AND SALE OF PROOF OF ORIGIN OF ELECTRICAL ENERGY VIRTUAL GLOBAL TRADING AG (CH) 2025-09-24 EP claimed
CN-118760842-B Music screening method and system for music treatment 佛山大学 2025-05-09 CN claimed
CN-114626286-B Transition pressure-in-package control method in ultrathin amorphous alloy production process 太原理工大学 2025-05-06 CN claimed
CN-119629631-A Mobile terminal security authentication method and system 北京卓高科技有限公司 2025-03-14 CN claimed
CN-119516343-A Self-adaptive sampling mechanism and double-step autocorrelation copying mobile tamper detection method 福建理工大学 2025-02-25 CN claimed
CN-119339730-A Digital audio embedding and detecting method 中国电影科学技术研究所(中央宣传部电影技术质量检测所) 2025-01-21 CN claimed
CN-119270799-A Water plant whole-flow intelligent optimal scheduling method based on self-adaptive feedback control 菏泽市水务集团万福供水有限公司 2025-01-07 CN claimed
EP-4183995-B1 HYDRAULICALLY RATE LIMITED VALVE HAMILTON SUNDSTRAND CORP (US) 2025-01-01 EP claimed
CN-119204306-A Method and device for collecting time series data of power grid information system based on reinforcement learning optimization 广东电网有限责任公司 2024-12-27 CN claimed
US-7365196-B2 Sulphonamido-substituted bridged bicycloalkyl derivatives MERCK SHARP & DOHME LTD. (GB) 2008-04-29 US claimed
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2007-03-22 US claimed
EP-1753734-A1 NITRIC OXIDE DONORS AND USES THEREOF RENOPHARM LTD. (IL) 2007-02-21 EP claimed
US-7173030-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2007-02-06 US claimed
EP-1268412-B1 SULPHONAMIDO-SUBSTITUTED BRIDGED BICYCLOALKYL DERIVATIVES MERCK SHARP & DOHME (GB) 2006-11-22 EP claimed
EP-1631558-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2006-03-08 EP claimed
WO-2005105765-A1 NITRIC OXIDE DONORS AND USES THEREOF RENOPHARM LTD. (IL) 2005-11-10 WO claimed
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2005-01-13 US claimed
WO-2004103980-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2004-12-02 WO claimed
US-20040029862-A1 Sulphonamido-substituted bridged bicycloalkyl derivatives MERCK CANADA INC. (CA) 2004-02-12 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 TDP1 926/4885TSHR 4126/4885SMN1; SMN2 3568/4885
US-20040029862-A1 Sulphonamido-substituted bridged bicycloalkyl derivatives BACE1, BACE2, PSEN2 TDP1 857/4885TSHR 4669/4885SMN1; SMN2 1594/4885
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD17B11 TDP1 1572/4885TSHR 3589/4885SMN1; SMN2 3079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.